To include your compound in the COVID-19 Resource Center, submit it here.

BB3: Phase II started

Angion began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE